Lv2
146 积分 2021-06-24 加入
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
23天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
1个月前
已完结
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
1个月前
已完结
An evaluation of becotatug vedotin for the treatment of recurrent or metastatic nasopharyngeal cancer
1个月前
已完结
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
2个月前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
2个月前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
2个月前
已完结
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
2个月前
已关闭
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
3个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
3个月前
已完结